논문 검색
-
Lenvatinib potentiates the antitumor efficacy of combined radiotherapy and PD-L1 blockade in lung adenocarcinoma.
[BACKGROUND] The potential of Lenvatinib to synergize with combined radiotherapy and immunotherapy in LUAD remains incompletely characterized. [METHODS] We investigated Lenvatinib's effects on radiation-induced PD-L1 in LUAD cells and VEGF…
FULLTEXT: Cellular Reprogramming randomized randomized versus -
Spatial transcriptomics unveils immune cellular ecosystems associated with patient survival in diffuse large B-cell lymphoma.
Diffuse large B-cell Lymphoma (DLBCL) is the most prevalent subtype of non-Hodgkin's lymphoma for which current therapeutic strategies remain insufficient, in part owing to heterogeneity in tumor biology and the immune microenvironment. The…
FULLTEXT: Cellular Reprogramming randomized randomized versus -
activates histone lactylation to promote gastric cancer progression and immune evasion through the HAS2/c-MYC/PD-L1 axis.
[BACKGROUND] Metabolic reprogramming and epigenetic alterations play important roles in driving tumor microenvironment (TME) remodeling and immune evasion in gastric cancer (GC). Histone lactylation links glycolytic metabolism to transcript…
FULLTEXT: Cellular Reprogramming randomized randomized versus -
The distinct roles of and in proximal- and late-onset colorectal cancer.
Despite the emerging role of the gut microbiome in colorectal cancer (CRC), its significance in early-onset CRC (EOCRC, …
FULLTEXT: Cellular Reprogramming randomized randomized versus -
Downregulation of the lncRNA PGM5P4-AS1 predicts poor prognosis and drives breast cancer progression through miR-3664-5p/KLF9.
[BACKGROUND] Accumulating evidence suggests that deregulated long non-coding RNAs (lncRNAs) drive breast cancer (BRCA) progression. This study investigated the expression profile and mechanism of PGM5P4 antisense RNA 1 (PGM5P4-AS1) in BRCA.…
FULLTEXT: Cellular Reprogramming randomized randomized versus -
Passive nuclear transport deviates from Fickian behavior in prostate and breast cell types.
Nuclear trafficking is essential for cellular function and biomedical applications such as nucleus-targeted drug delivery; however, how passive nuclear transport varies across cell types and phenotypic states remains poorly understood. Here…
FULLTEXT: Cellular Reprogramming randomized randomized versus -
The role of copper and cuproptosis in digestive system cancers: novel therapeutic strategies and mechanistic insights.
Recent research has highlighted the critical role of copper metabolism and a novel form of copper-dependent cell death, termed cuproptosis, in the progression and treatment of these cancers. Copper, an essential trace element, plays a cruci…
FULLTEXT: Cellular Reprogramming randomized randomized versus -
Dynamic changes in cellular mechanics and membrane microviscosity during migration of colorectal cancer cells.
The ability of tumor cells to migrate and invade adjacent tissue is a key property underlying the metastatic process. To ensure greater deformability and to facilitate movement, migratory cells undergo multiple changes in biophysical parame…
FULLTEXT: Cellular Reprogramming randomized randomized versus -
The interplay between autophagy, p16, and senescence in tumor cells: a systematic review.
Autophagy and cellular senescence are fundamental determinants of tumor cell fate. p16 has emerged as a key regulator at the intersection of these processes, yet its mechanistic role in the autophagy - senescence axis remains incompletely d…
FULLTEXT: Cellular Reprogramming randomized randomized versus -
Adding anti-PD-1 antibody to definitive chemoradiotherapy in elderly patients with esophageal squamous cell carcinoma: higher intensity does not equate to better outcomes.
[BACKGROUND AND PURPOSE] The benefit of adding anti-PD-1 antibodies to definitive chemoradiotherapy (dCRT) in elderly patients with esophageal squamous cell carcinoma (ESCC) remains uncertain. This study evaluated its efficacy and safety ve…
FULLTEXT: Cellular Reprogramming randomized randomized versus -
Economic evaluation of perioperative pembrolizumab plus standard of care as treatment for resectable locally advanced head and neck squamous cell carcinoma in the United States.
[AIMS] In the phase 3 KEYNOTE-689 trial (NCT03765918) among patients with resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC), perioperative pembrolizumab (pembrolizumab before surgery, then continued with standard-…
FULLTEXT: Cellular Reprogramming randomized randomized versus -
Cost-per-responder analysis of TAR-200 versus other Food and Drug Administration-approved novel and generic treatments among patients with Bacillus Calmette-Guérin-unresponsive, high-risk, non-muscle-invasive bladder cancer with carcinoma in situ in the United States.
[AIMS] Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with carcinoma (CIS) is aggressive and treatment options are suboptimal. TAR-200, a novel intravesical drug-releasing system, receiv…
FULLTEXT: Cellular Reprogramming randomized randomized versus -
A real-world study evaluating drug tolerability and health care resource use with acalabrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
[BACKGROUND AND AIM] Bruton tyrosine kinase inhibitors (BTKis) are the standard of care for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Ibrutinib and acalabrutinib are two commo…
FULLTEXT: Cellular Reprogramming randomized randomized versus -
Prolonged progression-free survival with zanubrutinib in relapsed/refractory CLL: an indirect treatment comparison versus other BTK inhibitors using multilevel network meta-regression.
[BACKGROUND] Bruton tyrosine kinase inhibitors (BTKis) are therapeutic agents for relapsed/refractory chronic lymphocytic leukemia (R/R CLL). Previous indirect treatment comparisons are limited in simultaneously comparing multiple intervent…
FULLTEXT: Cellular Reprogramming randomized randomized versus -
XPO1 Inhibition enhances sensitivity to platinum-based chemotherapy in germinal-center B-cell-like-DLBCL cells.
[PURPOSE] Platinum-based chemotherapy is considered as salvage therapy to relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients. However, treatment failure due to drug resistance occurs in some patients, particularly those with…
FULLTEXT: Cellular Reprogramming randomized randomized versus -
Phase angle as a nutritional assessment method in patients with acute myeloid leukemia: a cross-sectional study.
[BACKGROUND AND OBJECTIVES] The phase angle, which is associated with cellular health, has garnered increasing attention as a noninvasive and objective method for nutritional assessment. However, the association between malnutrition and pha…
FULLTEXT: Cellular Reprogramming randomized randomized versus -
The surgery for the patients with intestinal non‑Hodgkin lymphomas: a nationwide study.
[BACKGROUND] The treatment strategy for intestinal non-Hodgkin lymphoma (NHL) and the role of surgery warrant reevaluation. [METHODS] This study analyzed clinical data from a cohort of 12,047 patients diagnosed with intestinal NHL, extract…
FULLTEXT: Cellular Reprogramming randomized randomized versus -
NAD precursor supplementation reverses CD36-mediated lipid accumulation and ferroptosis to restore antitumor function of NK cells in DLBCL.
Natural killer (NK) cells play a key role in the standard treatment of diffuse large B-cell lymphoma (DLBCL). However, NK cells in DLBCL patients frequently display an exhausted phenotype, which is associated with poor clinical outcomes. Th…
FULLTEXT: Cellular Reprogramming randomized randomized versus -
A Randomized Trial Evaluating Intraoperative Ischemic Preconditioning of Parathyroid Glands During Total Thyroidectomy: A Signal for Earlier Parathyroid Function Recovery.
[BACKGROUND] Ischemic preconditioning of parathyroid glands (IPCP) is biologically plausible but clinical evidence is limited. In this single-center randomized trial (ChiCTR2000039788), we compared IPCP versus control during total thyroidec…
FULLTEXT: Cellular Reprogramming randomized randomized versus -
Integrating virtual screening and molecular dynamics simulations to identify emodin as a PYCR1 inhibitor modulating docetaxel sensitivity in prostate cancer.
Docetaxel (DTX) resistance is the main cause of treatment failure in castration-resistant prostate cancer (CRPC). Pyrroline-5-carboxylic acid reductase 1 (PYCR1) is an enzyme involved in proline metabolism. It is highly expressed in various…
FULLTEXT: Cellular Reprogramming randomized randomized versus